Fludarabine
- Generic Name
- Fludarabine
- Brand Names
- Fludara
- Drug Type
- Small Molecule
- Chemical Formula
- C10H12FN5O4
- CAS Number
- 21679-14-1
- Unique Ingredient Identifier
- P2K93U8740
- Background
Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.
- Indication
For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen
- Associated Conditions
- B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- -
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
- Conditions
- Disorder Related to Bone Marrow TransplantationLymphoma
- Interventions
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2020-12-29
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT00506129
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
FM 140 vs FM100 Study in Patients With Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2014-10-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 52
- Registration Number
- NCT00505895
- Locations
- 🇺🇸
UT MD . Anderson Cancer Center, Houston, Texas, United States
Busulfan and Fludarabine in Patients With AML and MDS
- First Posted Date
- 2007-07-18
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 200
- Registration Number
- NCT00502905
- Locations
- 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States
Cord Blood Expansion on Mesenchymal Stem Cells
- Conditions
- LeukemiaMyelodysplastic Syndrome
- Interventions
- Procedure: Cord Blood InfusionDrug: BusulfanDrug: FludarabineDrug: RituximabOther: ATGDrug: CyclophosphamideDrug: ClofarabineRadiation: Total Body Irradiation (TBI)Drug: MelphalanDrug: TacrolimusDrug: Mycophenolate MofetilDrug: G-CSF
- First Posted Date
- 2007-07-10
- Last Posted Date
- 2020-02-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 98
- Registration Number
- NCT00498316
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Non-Myeloablative Bone Marrow Transplant for Patients With Sickle Cell Anemia and Other Blood Disorders
- Conditions
- Sickle Cell Disease
- Interventions
- Drug: CyclophosphamideDrug: FludarabineDrug: Mycophenolate mofetilDrug: SirolimusProcedure: Allogeneic bone marrow transplantRadiation: Total body irradiation - 200Drug: LevetiracetamBiological: Anti-thymocyte globulinRadiation: Total body irradiation - 400
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2019-04-17
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 43
- Registration Number
- NCT00489281
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Acute Myeloid Leukemia
- First Posted Date
- 2007-06-20
- Last Posted Date
- 2008-11-18
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 47
- Registration Number
- NCT00488709
- Locations
- 🇪🇸
Hospital Sant Pau, Barcelona, Spain
🇪🇸Hospital Ntra. Sra. de Sonsoles, Avila, Spain
🇪🇸Hosptal Joan XXIII, Tarragona, Spain
SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia
- Conditions
- Myelodysplastic SyndromeAcute Myeloblastic Leukemia
- First Posted Date
- 2007-06-18
- Last Posted Date
- 2008-11-19
- Lead Sponsor
- PETHEMA Foundation
- Target Recruit Count
- 200
- Registration Number
- NCT00487448
- Locations
- 🇪🇸
Hospital Germans Trias i Pujol, Badalona, Spain
🇪🇸Hospital Universitario La Paz, Madrid, Spain
🇪🇸Hospital del Mar, Barcelona, Spain
Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
- Conditions
- Myelodysplastic SyndromesAcute Myeloid LeukemiaLeukemia
- Interventions
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT00480987
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Allogeneic Hematopoietic Stem Cell Transplant For Epidermolysis Bullosa
- Conditions
- Epidermolysis Bullosa
- Interventions
- Drug: busulfanDrug: cyclophosphamideDrug: fludarabine phosphateProcedure: hematopoietic bone marrow transplantation
- First Posted Date
- 2007-05-24
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 7
- Registration Number
- NCT00478244
- Locations
- 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome
- Conditions
- Myelofibrosis
- Interventions
- First Posted Date
- 2007-05-17
- Last Posted Date
- 2019-05-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 63
- Registration Number
- NCT00475020
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.